TP53 Clinical Trials

5 recruiting

TP53 Trials at a Glance

14 actively recruiting trials for tp53 are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Boston, Minneapolis, and Beijing. Lead sponsors running tp53 studies include Dana-Farber Cancer Institute, Masonic Cancer Center, University of Minnesota, and Chinese PLA General Hospital.

Browse tp53 trials by phase

Treatments under study

About TP53 Clinical Trials

Looking for clinical trials for TP53? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new TP53 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about TP53 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NeoplasmsLi-Fraumeni SyndromeTp53 Mutations
National Cancer Institute (NCI)5,000 enrolled2 locationsNCT01443468
Recruiting

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

Medulloblastoma RecurrentMedulloblastoma, Childhood, RecurrentMedulloblastoma, SHH-activated and TP53 Mutant+1 more
Mohammad H. Abu Arja300 enrolled2 locationsNCT07242963
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

Hereditary Cancer SyndromeLi-Fraumeni SyndromeTP53 Gene Mutation+2 more
Dana-Farber Cancer Institute1,500 enrolled3 locationsNCT04541654
Recruiting
Phase 1

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Advanced Solid TumorsTP53 Y220C Mutation
PMV Pharmaceuticals, Inc14 enrolled5 locationsNCT07372625
Recruiting

Germline Genetic Testing of the TP53 Gene

TP53 Gene MutationMulti-Gene Transcriptional ProfilingTP53 Gene Germline Mutation Carrier
European Institute of Oncology1,940 enrolled1 locationNCT07419893
Recruiting
Phase 2

ALPINE: Maintenance Letrozole/Abemaciclib

Endometrial CancerTP53Recurrent Endometrial Cancer
Dana-Farber Cancer Institute32 enrolled6 locationsNCT06366347
Recruiting
Phase 1

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd.82 enrolled1 locationNCT06908434
Recruiting
Phase 2

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

TP53Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University24 enrolled1 locationNCT07240194
Recruiting
Phase 1Phase 2

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Acute Myeloid LeukemiaTP53
Masonic Cancer Center, University of Minnesota32 enrolled1 locationNCT07008638
Recruiting
Phase 2

Oral-ATO for TP53-mutated Myeloid Malignancies

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Neoplasm+2 more
The University of Hong Kong30 enrolled1 locationNCT06778187
Recruiting
Phase 2

AZA Combined With RCHOP in P53-mutated DLBCL.

DLBCL - Diffuse Large B Cell LymphomaTP53
The First Affiliated Hospital of Xiamen University52 enrolled1 locationNCT06158399
Recruiting
Phase 2

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial CarcinomaTP53 MutationRecurrent or Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences117 enrolled1 locationNCT06413992
Recruiting
Phase 1

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Solid Tumor, AdultLymphomaEphA2 Overexpression+4 more
Chinese PLA General Hospital10 enrolled1 locationNCT05631886